non small-cell lung cancer (NSCLC)
Patent oppositions filed in

Osimertinib is a kinase inhibitor used as targeted therapy. It is prescribed for treating non small-cell lung cancer (NSCLC).

This drug is missing the following documents, can you help us by contributing something?


Information related to relevant oppositions from around the world.

Patent Oppositions

The table includes oppositions aimed at contesting patents covering this drug. Note that at the country level, several patent applications can cover the same drug.

Please pay attention not only to the patent opposition, but also to the patent application it relates to, see column "Related Patent Application". To better identify similarities, the column "Patent Type" indicates a general classification of the patent. Arguments used to contest a specific type of patent may apply for another that fits in the same category.

CountryDateWho FiledOpposition typeOpposition statusPatent typeRelated patent applicationMore info
Argentina04-01-2021CILFAPre-GrantUnder ExaminationPolymorphsAR115019A2View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top